262 related articles for article (PubMed ID: 22122233)
21. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin.
Magnusson MO; Dahl ML; Cederberg J; Karlsson MO; Sandström R
Clin Pharmacol Ther; 2008 Jul; 84(1):52-62. PubMed ID: 17971810
[TBL] [Abstract][Full Text] [Related]
23. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin.
Zhang JG; Ho T; Callendrello AL; Crespi CL; Stresser DM
Drug Metab Lett; 2010 Dec; 4(4):185-94. PubMed ID: 20583967
[TBL] [Abstract][Full Text] [Related]
24. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
25. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies.
Kenny JR; Chen L; McGinnity DF; Grime K; Shakesheff KM; Thomson B; Riley R
Xenobiotica; 2008 Dec; 38(12):1500-17. PubMed ID: 18989830
[TBL] [Abstract][Full Text] [Related]
26. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
[TBL] [Abstract][Full Text] [Related]
27. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
28. The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.
Chen X; Jacobs G; de Kam M; Jaeger J; Lappalainen J; Maruff P; Smith MA; Cross AJ; Cohen A; van Gerven J
Br J Clin Pharmacol; 2014 Dec; 78(6):1298-314. PubMed ID: 24802722
[TBL] [Abstract][Full Text] [Related]
29. Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
Dong JQ; Gosset JR; Fahmi OA; Lin Z; Chabot JR; Terra SG; Le V; Chidsey K; Nouri P; Kim A; Buckbinder L; Kalgutkar AS
Drug Metab Dispos; 2017 May; 45(5):501-511. PubMed ID: 28254951
[TBL] [Abstract][Full Text] [Related]
30. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Iwamoto M; Kassahun K; Troyer MD; Hanley WD; Lu P; Rhoton A; Petry AS; Ghosh K; Mangin E; DeNoia EP; Wenning LA; Stone JA; Gottesdiener KM; Wagner JA
J Clin Pharmacol; 2008 Feb; 48(2):209-14. PubMed ID: 18077730
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.
Schmider J; Brockmöller J; Arold G; Bauer S; Roots I
Pharmacogenetics; 1999 Dec; 9(6):725-34. PubMed ID: 10634135
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
33. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
34. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
35. Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy.
Qiu R; Fonseca K; Bergman A; Lin J; Tess D; Newman L; Fahmy A; Useckaite Z; Rowland A; Vourvahis M; Rodrigues D
Clin Transl Sci; 2024 Jan; 17(1):e13644. PubMed ID: 38108609
[TBL] [Abstract][Full Text] [Related]
36. Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays.
Murayama N; Usui T; Slawny N; Chesné C; Yamazaki H
Drug Metab Lett; 2015; 9(1):3-7. PubMed ID: 25600204
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Haas CE; Brazeau D; Cloen D; Booker BM; Frerichs V; Zaranek C; Frye RF; Kufel T
Eur J Clin Pharmacol; 2005 Sep; 61(8):583-93. PubMed ID: 16041547
[TBL] [Abstract][Full Text] [Related]
38. Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells.
Wang QL; Wu Q; Tao YY; Liu CH; El-Nezami H
Hepatobiliary Pancreat Dis Int; 2011 Oct; 10(5):502-8. PubMed ID: 21947724
[TBL] [Abstract][Full Text] [Related]
39. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Xu Y; Zhou Y; Hayashi M; Shou M; Skiles GL
Drug Metab Dispos; 2011 Jul; 39(7):1139-48. PubMed ID: 21441468
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Sathe AG; Othman AA; Mohamed MF
J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
